In last trading session, Verve Therapeutics Inc (NASDAQ:VERV) saw 1.36 million shares changing hands with its beta currently measuring 1.69. Company’s recent per share price level of $6.42 trading at $0.26 or 4.22% at ring of the bell on the day assigns it a market valuation of $570.07M. That closing price of VERV’s stock is at a discount of -126.95% from its 52-week high price of $14.57 and is indicating a premium of 33.02% from its 52-week low price of $4.30. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.59 million shares which gives us an average trading volume of 1.55 million if we extend that period to 3-months.
For Verve Therapeutics Inc (VERV), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 8 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.65 in the current quarter.
Verve Therapeutics Inc (NASDAQ:VERV) trade information
Upright in the green during last session for gaining 4.22%, in the last five days VERV remained trading in the red while hitting it’s week-highest on Friday, 03/07/25 when the stock touched $6.42 price level, adding 5.73% to its value on the day. Verve Therapeutics Inc’s shares saw a change of 13.83% in year-to-date performance and have moved -1.98% in past 5-day. Verve Therapeutics Inc (NASDAQ:VERV) showed a performance of -19.55% in past 30-days. Number of shares sold short was 14.86 million shares which calculate 11.12 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 14.5 to the stock, which implies a rise of 55.72% to its current value. Analysts have been projecting 14 as a low price target for the stock while placing it at a high target of 15. It follows that stock’s current price would drop -118.07% in reaching the projected high whereas dropping to the targeted low would mean a loss of -118.07% for stock’s current value.
Verve Therapeutics Inc (VERV) estimates and forecasts
This year revenue growth is estimated to fall -25.30% from the last financial year’s standing.
9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 9.38M for the same. And 9 analysts are in estimates of company making revenue of 4.79M in the next quarter. Company posted 5.7M and 6.69M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -42.43% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -12.88% while estimates for its earnings growth in next 5 years are of -4.16%.
Verve Therapeutics Inc (NASDAQ:VERV)’s Major holders
Insiders are in possession of 5.04% of company’s total shares while institution are holding 90.05 percent of that, with stock having share float percentage of 94.84%. Investors also watch the number of corporate investors in a company very closely, which is 90.05% institutions for Verve Therapeutics Inc that are currently holding shares of the company. ALPHABET INC. is the top institutional holder at VERV for having 12.35 million shares of worth $60.26 million. And as of 2024-06-30, it was holding 14.6618 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 6.62 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.9632 of outstanding shares, having a total worth of $32.31 million.
